Janux Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 24.2, 4.18, 13.29, 74.01, 159.68 ], "ebit_estimate": [ -150.74, -216.81, -266.76, -296.2, -294.88 ], "ebitda_estimate": [ -160.79, -220.31, -248.54, -245.87, null ], "net_income_estimate": [ -120.47, -187.91, -236.27, -261.75, -238.51 ], "per_share_eps_estimate": [ -1.86, -2.82, -3.49, -3.86, -3.73 ], "eps_nri_estimate": [ -1.89, -2.76, -3.36, -3.55, -3.4 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 14.44, 11.42, 8.72, null, null ], "pretax_income_estimate": [ -115.74, -188.41, -233.25, -251.54, -222.79 ], "operating_cash_flow_per_share_estimate": [ -0.83, -2.07, -2.43, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -8.3, -15.96, -24.38, null, null ], "gross_margin_estimate": [ 100, 100, 100, 91, 90.35 ], "operating_cash_flow_estimate": [ -52.01, -129.72, -152.28, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -24.6, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -26.45, "future_eps_nri_estimate_growth": -24.6, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -21.42, "future_ebitda_estimate_growth": -18.76, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -18.03, "future_pretax_income_estimate_growth": -30.28, "future_book_value_per_share_estimate_growth": -18.34, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -31.29 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 13.02, 4.08, 6.89, null, null, null, null, 3.3 ], "ebit_estimate": [ -24.56, -40.45, -44.1, -48.76, -50.5, -52.26, -54.02, -55.28 ], "ebitda_estimate": [ -28.71, -37.71, -55.05, -54, -55, -56, -57, null ], "net_income_estimate": [ -27.66, -32.26, -32.49, -41.28, -43.13, -44.98, -46.85, -44.82 ], "per_share_eps_estimate": [ -0.47, -0.54, -0.56, -0.72, -0.75, -0.79, -0.81, -0.66 ], "eps_nri_estimate": [ -0.42, -0.53, -0.59, -0.68, -0.71, -0.74, -0.77, -0.82 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -23.89, -34.21, -30.59, -41.28, -43.13, -44.98, -46.85, -44.82 ], "operating_cash_flow_per_share_estimate": [ 0.11, -0.51, -0.57, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ 2.51, -13.24, -15.45, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100, null ], "operating_cash_flow_estimate": [ 6.89, -31.96, -35.72, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -24.6, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -26.45, "future_eps_nri_estimate_growth": -24.6, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -21.42, "future_ebitda_estimate_growth": -18.76, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -18.03, "future_pretax_income_estimate_growth": -30.28, "future_book_value_per_share_estimate_growth": -18.34, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -31.29 }